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Pathogenic Amyloid-b DomainArne Schreiber,† Sebastian Fischer,† and Thorsten Lang†*
†Department of Membrane Biochemistry, Life and Medical Sciences (LIMES) Institute, University of Bonn, Bonn, GermanyABSTRACT The amyloid precursor protein (APP) is a large, ubiquitous integral membrane protein with a small amyloid-
b (Ab) domain. In the human brain, endosomal processing of APP produces neurotoxic Ab-peptides, which are involved in
Alzheimer’s disease. Here, we show that the Ab sequence exerts a physiological function when still present in the unpro-
cessed APP molecule. From the extracellular site, Ab concentrates APP molecules into plasmalemmal membrane protein
clusters. Moreover, Ab stabilization of clusters is a prerequisite for their targeting to endocytic clathrin structures. Therefore,
we conclude that the Ab domain directly mediates a central step in APP trafficking, driving its own conversion into neurotoxic
peptides.INTRODUCTIONThe human amyloid precursor protein (APP) gene encodes
for a ubiquitously expressed type I integral membrane
protein with a large extracellular domain and a short cyto-
plasmic region (1). Three major isoforms, ranging from
695 to 770 amino acids (aa) in length, have been identified.
APP first attracted attention when one of its degradation
products, the ~40-aa large b-amyloid (Ab) peptide, was
found in senile brain plaques isolated from Alzheimer’s
patients (2). Though the primary function of APP still
remains elusive, most research focuses on the function and
generation of the Ab cleavage product.
To date, it is clear how Ab peptides are generated and also
that alternative APP degradation pathways exist. For Ab
production, the enzymes b- and g-secretase are required
to cleave the Ab sequence at its N- and C-terminal ends,
respectively (3). As b-secretase functions in early endo-
somes (4–6), endocytic uptake of APPmolecules is a prereq-
uisite for amyloidogenic processing. Alternatively, the Ab
region is cleaved at its center by plasmalemmal a-secretase,
yielding harmless fragments (nonamyloidogenic pathway).
After processing and secretion of Ab peptides, Ab oligo-
mers or fibrils play a central role in the development of
Alzheimer’s disease (7). Moreover, several nonpathogenic
activities of Ab peptides have been discussed (for example,
see Baruch-Suchodolsky et al. (8), Igbavboa et al. (9), and
Zou et al. (10)). However, so far it is unknown whether the
Ab domain has a function when still present in the unpro-
cessed molecule (for exception, see Tienari et al. (11)).
Interfering with trafficking or processing of APP might
reduce the progression of the disease (12,13), for instance,
by taking advantage of a- and b-secretase being active at
the plasma membrane and in early endosomes, respectively.
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amyloidogenic processing (14).
Internalization of APP occurs via a clathrin-mediated
pathway (15). Moreover, it is known that endocytosis of
APP is regulated by a flotillin-dependent APP clustering
step (16). However, flotillin rather acts as a modulator of a
more intrinsic clustering mechanism, since clusters become
smaller but still remain after flotillin downregulation (16).
Here, we examine the mechanism of APP clustering in
the plasma membrane, as understanding APP clustering is
important for understanding APP trafficking, which in turn
is a prerequisite for the development of therapeutic strate-
gies against Alzheimer’s disease.MATERIALS AND METHODS
Cloning of APP constructs
The expression vector used for all constructs was pcDNA6.2/C-emGFP/
DEST(V355-20, Invitrogen,Carlsbad,CA).N-terminallymyc-taggedhuman
APP695 (NCBI reference sequence NM_201414 with VPEQKLISEEDL
inserted between positions 19 and 20 (11,17)) was inserted via PCR/Gateway
cloning (Invitrogen) into the expression vector, resulting in C-terminally
GFP-tagged myc-APP with a KGGRADPAFLYKVVDAVN linker between
APPandGFP.Following the sameprocedure, aC-terminally deleted construct
was obtained (APP-DC; lacking aa 649–695 of the original APP sequence).
ForN-terminal deletion, a cDNAsequencewas obtained fromMWGEurofins
(Ebersberg, Germany) and inserted via PCR/Gateway cloning into the expres-
sion vector (APP-DN; lacking aa 18–601). The myc-tagged full-length APP
was used in Figs. 1 and 2, Fig. S1, Fig. S2, and Fig. S4 C. For Figs. 3–5,
Fig. S3, Fig. S5, and Fig. S6, we used APP without myc-tag that was cloned
by using the Acc65I and EcoRI restriction sites within the APP sequence. To
this end, a double-digested PCRproductwas inserted into the double-digested
pcDNA6.2/C-emGFP/DEST expression vector from the myc-tagged APP,
resulting in a construct without the VPEQKLISEEDL insert. From this
plasmid, using the restriction sites Acc65I and EcoRI or Acc65I and SgsI,
deletion constructs were produced (the deletions D22–283, D22–435,
D22–537,D22–596, andD22–601). In addition, fusionPCRproducts carrying
the mutations N467S and/or T291G, T292G and T576G were amplified and
inserted into the expression vector.
Using the NCBI reference sequence NM_201414 as reference, the APP
coding sequence of all constructs was verified by sequencing. Comparativedoi: 10.1016/j.bpj.2012.02.031
FIGURE 1 APP mobility is restricted via the
N-terminal extracellular domain. (A) Confocal
micrographs were recorded from PC12 cells ex-
pressing GFP-tagged APP (upper) and variants
with an N-terminal deletion (APP-DN; lower) or
a C-terminal deletion (APP-DC; not shown). Fluo-
rescence bleaching was performed in a squared
ROI (dotted square) at the basal plasma membrane
(compare first and second images). Recovering
fluorescence was related to the prebleach value.
For one experiment, normalized recovery traces
from several cells were averaged for calculation
of the half-time of recovery. (B and C) Averaged
experiments. Values are given as the mean 5 SE
(n ¼ 3–5).
1412 Schreiber et al.fluorescence recovery after photobleaching (FRAP) analysis showed no
difference between the two full-length APP constructs (with and without
myc-tag; data not shown).
Cell culture
PC12 cells were maintained, propagated, and plated onto poly-L-lysine
coated coverslips essentially as previously described (18). HepG2 cells
were propagated in EMEM (BE12-992F, Lonza, Basel, Switzerland) supple-
mentedwith 10%fetal calf serumand1%Pen/Strep at 37Cand5%CO2. For
transfection, we used a Microporator MP100 (Digital Bio, Seoul, South
Korea) or a Neon-Transfection System (Invitrogen) applying 100-ml gold
tips, adding 10–25 mg plasmid/transfection tip and adjusting settings to
1410 V and 30 ms for PC12 cells or 1200 V and 50 ms for HepG2 cells.
For Fig. S4, cells were treated before the FRAP experiment with deglycosy-
lating enzymes a-neuraminidase (0.5 U/ml) and peptide-N-glycosidase
(0.1 U/ml) (N2876 and G5166, respectively, Sigma, St. Louis, MO) and
b-galactosidase (0.16 U/ml; P07305, New England Biolabs, Ipswich, MA)
in serum-free medium for 1 h at 37C in the cell incubator. Then cells
were mounted into a microscopy chamber in Ringer solution (130 mMFIGURE 2 APP disperses after deletion of the extracellular domain.
TIRF microscopy images from PC12 cells expressing the same constructs
as in Fig. 1, illustrating that APP disperses upon deletion of the extracellular
domain (APP-DN), whereas it remains clustered without the intracellular
C-terminal domain (APP-DC). Images are shown at arbitrary scaling.
Biophysical Journal 102(6) 1411–1417NaCl, 4 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 48 mM glucose, and
10 mM HEPES, pH 7.4). Cells were used ~8 h (Figs. 3–5, Fig. S3, Fig. S4,
Fig. S5, and Fig. S6), 24 h (Figs. 1 and 2 and Fig. S2), and 8–24 h
(Fig. S1) after transfection.FRAP analysis
FRAP measurements in Ringer solution at room temperature (RT) and
analyses were performed using an Olympus Fluo View 100 laser scanning
microscope essentially as described previously (18). In brief, the pixel size
was adjusted to 207 nm and the image size to 100 100 pixel, and bleaching
was performed in a 15 15 pixel region of interest (ROI) using the 488-nm
and 405-nm laser lines simultaneously. Depending on the experiment,
bleaching duration varied from 1–2 s. In total, a sequence of 70 images
was recorded, including three prebleach and 67 postbleach images. For anal-
ysis, apart from the bleaching ROI, values were obtained from a reference
ROI in an unbleached area and a background value was determined.
Recovery traces were background-subtracted and normalized to the average
of the prebleach values. Vertical drift during the measurement was indicated
by a loss of fluorescence in the reference ROI. When the value of the refer-
ence ROI decreased by >15%, the measurement was excluded.
The half-time of recovery was obtained by fitting a hyperbola (y(t)¼ off-
set þ maxrec  t/(t þ t1/2)) using Origin8Pro (OriginLab, Northampton,
MA). For one experiment and condition, 3–11 cells were analyzed and
half-times and normalized recovery traces were averaged.
The diffusion coefficient of a freely diffusing single-span membrane
protein has been reported to be 0.23 mm2/s (19), which corresponds to
the value 0.13 of the normalized half-time (Fig. 3).TIRF microscopy
Total internal reflection fluorescence (TIRF) microscopy was performed
essentially as already described (18). Cells were imaged at RT in Ringer
solution (n ¼ 3–4 independent experiments).
FIGURE 3 Entire Ab domain is essential for mobility restriction of APP.
(A) FRAP recovery traces (as in Fig. 1 B) from APP constructs carrying the
indicated deletions within the ectodomain. (B) Half-times were normalized
to full-length APP and plotted against the number of deleted aa. The shad-
owed area indicates the half-time zone for a freely diffusing single-span
membrane protein (see also Materials and Methods). The erratic increase
in mobility from construct D22–596 to D22–601 indicates a change from
restricted to free diffusion. Please note that the two constructs differ by
only five aa from the N-terminus of the amyloid b region. (Upper) Domain
structure of APP (not to scale; referring to Reinhard et al. (29)). Dashed
lines roughly indicate the position of the last deleted amino acid of the
respective construct. GFLD, N-terminal growth-factor-like domain;
CuBD, copper-binding domain; AcD, acidic domain; RERMS, five-aa
peptide sequence; CAPPD, central APP domain; L, linker; Ab, amyloid-b
peptide sequence; AICD, APP intracellular domain. Values are given as the
mean5 SE (n ¼ 3–12).
FIGURE 4 Truncation of Ab is accompanied by cluster dispersion. Fixed
membrane sheets generated from cells expressing the constructs as indi-
cated. From individual membrane sheets the SD of the mean intensity
was determined in a ROI and related to the mean background-corrected
fluorescence, yielding the relative SD, which is a quantitative measure
for the degree of clustering (18). For each construct, data from three to
four independent experiments were pooled. From individual membrane
sheets, the relative SD was plotted against the mean intensity and a function
f(x) ¼ axb was fitted (APP, a ¼ 0.9961 and b ¼ 0.295; APPD22–596,
a ¼ 1.169 and b ¼ 0.321; APPD22–601, a ¼ 0.7785 and b ¼ 0.295).
Please note that maximal and minimal values obtained at low and high
expression levels are a consequence of mathematical processing and do
not necessarily indicate that clusters disappear at high expression levels
(the same effect is expected if clusters just become more numerous).
Full-length APP (blue line) and APPD22–596 (red line) have the same
degree of clustering, whereas the predominantly uniform distribution of
APPD22–601 (green line) is indicated by a shift of the fitted line toward
lower values. For each condition, 62–105 individual membrane sheets
were analyzed. Images are shown at arbitrary scaling.
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For Fig. S4, cells were pretreated with deglycosylating enzymes as above.
Then membrane sheets were generated (18) and fixed with 4% paraformal-
dehyde (PFA) in phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM
KCl, and 8.1 mM Na2HPO4, pH7.4) for 1 h. PFA was quenched with
50 mM NH4Cl in PBS and membrane sheets were incubated with 5 mg/ml
Alexa594-labeled wheat germ agglutinin (WGA) (W11262, Invitrogen) in
PBS. Membrane sheets were washed with PBS and imaged in PBS contain-
ing 1-(4-tri-methyl-ammonium-phenyl)-6-phenyl-1,3,5-hexatriene p-tolue-
nesulfonate (TMA-DPH) (T204, Molecular Probes, Eugene, OR). Imaging
and image analysis (using the program ImageJ) were performed as
described (18). For each independent experiment and condition, 24–39
membrane sheets were analyzed and values were averaged.Immunostaining of membrane sheets
Immunostaining was performed according to a protocol essentially as
previously described (18). For clathrin staining, a goat antibody directedagainst the clathrin heavy chain (sc-6579, Santa Cruz Biotechnology, Santa
Cruz, CA) and, as secondary antibody, a donkey-anti-goat antibody coupled
to Alexa594 (A11058, Invitrogen) were used. Membrane sheets were
imaged in the presence of TMA-DPH to illustrate the integrity of the
membrane. Membrane sheets with the expressed constructs were identified
in the green channel and then imaged in the blue, green, and red channels to
show the lipid staining (TMA-DPH fluorescence), GFP-fluorescence, and
clathrin staining, respectively.
To correct for lateral shifts occurring during channel switching, and to
ensure that the focus was properly adjusted, we added 100 nm TetraSpeck
beads (T7279, Invitrogen/Molecular Probes) to the coverslip that were
detectable in all channels. The correlation coefficient was determined
using ImageJ, applying the ImageJ plugin Colocalization Indices (20).
For each independent experiment and condition, 4–14 membrane sheets
were analyzed and their values were averaged. For full-length APP, we
also analyzed the overlap of APP and clathrin on the level of individualBiophysical Journal 102(6) 1411–1417
FIGURE 5 Targeting of APP into clathrin structures requires the entire
Ab- and the intracellular domain. Membrane sheets from PC12 cells ex-
pressing GFP-tagged APP, APPD22–283 (not shown), APPD22–596,
APPD22–601, or APP-DC were fixed and immunostained for clathrin.
Shown from left to right are TMA-DPH staining visualizing the integrity
of the plasma membrane; the GFP channel showing the distribution of
the respective APP construct; clathrin staining indicating endocytic clathrin
structures and an overlay of GFP/clathrin signals. From central areas, the
correlation between the GFP and the clathrin staining patterns was quanti-
fied by calculation of the Pearson correlation coefficient. The coefficient
yields 1 in the case of two identical pictures (realistic values are much lower
due to technical reasons), 0 when signals are unrelated, and 1 in the case
of a picture and its negative. On the level of individual spots, the value of
0.32 obtained for full-length APP corresponds to 54% of APP clusters
that are positive for clathrin (Fig. S6). Values are given as the mean5 SE
(n ¼ 3–4). Images are shown at arbitrary scaling.
1414 Schreiber et al.spots (Fig. S6) and corrected for accidental colocalization as previously
described (21).Detection of constructs at the cell surface
For detection of GFP-labeled APP, APPD22–596, and APPD22–601 at the
cell surface, we followed a protocol essentially as previously describedBiophysical Journal 102(6) 1411–1417(16). In brief, PC12 cells expressing the respective constructs were cooled
down in the cold room on ice, and all the steps described here were per-
formed with ice-cold solutions. Cells were washed with Hank’s BSS
(HBSS; cat# H15-008, PAA Laboratories, Co¨lbe, Germany) and incubated
for 30 min with a mouse monoclonal primary antibody (1:100 in HBSS;
SIG-39300, Covance, Princeton, NJ) reactive for aa 1–16 of the Ab peptide.
Then cells were washed and incubated for 40 min with secondary antibody
donkey-anti-mouse coupled to Alexa594 (1:200 in HBSS; A21203, Invitro-
gen). Cells were washed and fixed overnight in 4% PFA in PBS. Quenching
of PFAwith NH4Cl and embedding in Mowiol (6 g glycerol, 2.4 g Mowiol
(4-88, Hoechst, Frankfurt, Germany), 6 ml ddH2O, and 12 ml of 200 mM
Tris, pH 7.2) saturated with Dabco (0718.1, Carl Roth, Karlsruhe,
Germany) was performed at RT. For imaging, we used the Olympus Fluo
View 100 laser scanning microscope, applying the laser line 488 for GFP
and the laser line 543 for Alexa594. In addition, cells were imaged in
the differential interference contrast (DIC) mode. For analysis, we used
ImageJ. In brief, using the DIC image as reference, a linescan was placed
at the rim of the cell. In the green (GFP) and red (immunostaining) channels,
the average intensities per pixel were measured and background-corrected.
Pooling data from several independent experiments, immunostaining
intensity was plotted against GFP fluorescence for each cell.RESULTS AND DISCUSSION
Clustered membrane proteins are restricted in diffusion (see,
e.g., Zilly et al. (18) and He and Marguet (22)). Therefore, to
probe the clustered state of APP molecules, we analyzed its
diffusional mobility by FRAP. For fluorescent labeling, GFP
was fused to the C terminus of the 695-aa large neuronal
APP isoform and the construct was expressed in neuronal
and liver model cell lines. For FRAP analysis, we focused
on the basal plasma membrane, bleached fluorescence in
a squared ROI, and monitored the recovery of fluorescence
over time. The recovery rate was much slower than expected
for free diffusion, although it was somewhat dependent on
the time after expression, becoming accelerated between
8 and 24 h after transfection (Fig. S1). To test which protein
domains restrict mobility in neuronal cells, we analyzed
diffusion of a deletion construct lacking the complete extra-
cellular domain (APP-DN) and found a severalfold higher
mobility when compared to full-length APP (Fig. 1). We
then asked whether this increased mobility is indeed due
to a change from clustered to uniform molecule organiza-
tion. To this end, we applied TIRF microscopy, which selec-
tively illuminates the plasma membrane region, avoiding
the imaging of deeper-lying intracellular compartments.
As shown in Fig. 2, the majority of APP fluorescence
was concentrated into punctate structures, whereas upon
removal of the ectodomain (APP-DN) the distribution
became uniform with additional spotty signals occasionally
seen. This is in line with our assumption that fast and slow
diffusion in FRAP experiments correspond to low and high
degrees of protein clustering, respectively. Next, we deleted
the intracellular domain (construct APP-DC, with the full
extracelluar domain intact). The mobility was slightly
increased (Fig. 1, B and C), and the distribution of APP-DC
still had a clustered appearance in TIRF micrographs,
although it was less clear than for APP (Fig. 2). Analysis
APP Clustering via the Amyloid-b Domain 1415of the deletion constructs in liver cells (Fig. S2) revealed
identical results, implying that neuronal factors are not
involved in the basic APP clustering mechanism.
So far, the data suggest that the extracellular domain of
APP is essential for concentrating the protein into clusters
in the membrane. In the absence of the intracellular domain,
clusters still form but become more dynamic, in line with
the presence of modulators stabilizing APP clusters from
the intracellular side.
The extracellular domain could mediate APP clustering
by several mechanisms. For instance, APP contains glyco-
sylation sites in the ectodomain (23,24) that could interact
with or be part of the extracellular glycocalyx. Other possi-
bilities are that the bulkiness of the ectodomain could
restrict mobility, or a special protein domain could be
responsible for clustering. To test the first possibility, we
performed FRAP experiments on cells with APP harboring
point mutations at the glycosylation sites (Fig. S3) or cells
with a degraded glycocalyx (Fig. S4). However, APP
diffused normally, ruling out a role of the glycocalyx. We
then performed FRAP analysis with progressively shorter
constructs (Fig. 3). Over awide sequence range, the deletions
caused only small mobility enhancements approximately
linear to the number of removed aa. This observation
might be due to friction forces, which can be expected to
be reduced with the smaller geometric sizes of the extracel-
lular domains. In any case, because deletion of almost
the entire ectodomain (construct APPD22–537) raised the
mobility only modestly (Fig. 3), we can conclude that the
globular size of the ectodomain does not produce a clustering
pattern due to restriction by extracellular diffusion barriers
(for a suggested mechanism based on intracellular diffu-
sion barriers, see Kusumi et al. (25)). Notably, the mobility
changed upon further deletion, with a remarkable stepwise
increase caused by removing the first five aa of the Ab
region. These findings strongly suggest that APP clustering
ismediated primarily through a specific interaction involving
the N-terminal region of the Ab domain, although some
stabilizing effect of the more upstream-lying aa is notable.
To verify that the protein disperses upon Ab-shortening, we
compared the lateral distribution of APP to the distributions
of the two shortest variants, APPD22–596 andAPPD22–601,
applying fixed plasma membrane sheets (Fig. 4). Plasma
membrane sheets were generated by brief ultrasound treat-
ment of glass-adhered cells, leaving behind the basal plasma
membrane. This preparation allows for high signal/noise
ratio analysis of fluorescence signals. Moreover, unlike
TIRF microscopy, it can be used to exclude the possibility
that uniform fluorescence results from cytosolic GFP or
that punctate signals arise from undocked vesicles close to
themembrane (see also Fig. S5 for a surface staining showing
the presence of the constructs within the plasma membrane).
As shown in Fig. 4, both APP and APPD22–596 show a
strongly clustered pattern, whereas APPD22–601 is predom-
inantly uniformly distributed. This corroborates the conclu-sions drawn from the FRAP experiments, that the first aa
of the Ab-region dramatically affect the lateral organization
of APP by immobilizing APP into clusters.
We then asked if clustering is an event associated with
endocytosis and compared the APP clustering pattern to
the distribution of clathrin. A high degree of overlap was
measured only for constructs possessing both the Ab and
the intracellular domain, though the still clustered, but
already more dynamic, APPD22–596 less efficiently corre-
lated with clathrin. Compared to full-length APP, the
construct with the partially deleted Ab domain was almost
fivefold less targeted to endocytic structures. This indicates
that a certain degree of cluster stability is required for effi-
cient entry into the endocytic pathway. We also tested the
construct lacking the intracellular domain (APP-DC). As ex-
pected, APP-DC did not incorporate into clathrin structures,
instead even showing some trend toward being excluded
from the clathrin staining pattern (Fig. 5).
In summary, the data show that a few aa within the Ab
region are sufficient for the formation of APP clusters. In
contrast, the intracellular domain of APP is incapable of
forming clusters on its own, though it gives additional stabi-
lization to Ab-formed clusters from the intracellular site.
As shown by our clathrin staining experiments, the intra-
cellular portion of APP directs the molecule into endocytic
structures. At present, it is unclear whether clathrin is re-
cruited to the site of clustering or whether clustered APP
becomes trapped into clathrin assemblies, but we can safely
conclude that the process is only effective upon APP immo-
bilization by Ab. Probably, clathrin structures interfere with
the dynamics of APP clusters, explaining the slight increase
in APP mobility upon removal of the intracellular domain.
In any case, the data show that tight clustering is a prerequi-
site for directing APP efficiently to the endocytic pathway.
Therefore, we conclude that APP clustering and immobili-
zation is a key step in APP trafficking from the plasma
membrane via clathrin-coated vesicles to early endosomes
(Fig. 6).
Inhibition of b-secretase function has already been sug-
gested (13,26) as a means to prevent Alzheimer’s disease,
but it would require a pharmaceutical with intracellular
activity and would carry the risk of possible side effects
due to inhibition of an enzyme that also has physiological
relevance (27). In contrast, prevention of APP clustering
into endocytic structures requires the pharmaceutical to
act only from the extracellular site (Fig. 6). Moreover, in
analogy to a mechanism suggested to produce shorter Ab
peptides when interfering with GxxxG-motif-mediated
APP dimerization (28), dispersed APP may allow g-secre-
tase to bind the APP molecule farther upstream, leading to
the production of shorter and less harmful Ab peptides.
In a nutshell, our data show that for APP clustering, the
Ab-domain is essential. Moreover, clustering is a prerequi-
site for targeting APP to endocytic structures. These find-
ings indicate what we consider a novel central step in APPBiophysical Journal 102(6) 1411–1417
FIGURE 6 APP cluster formation within the plasma membrane. Unpro-
cessed APP molecules reach the cell surface through the constitutive secre-
tory pathway, where they cluster via the N-terminal aa of Ab. APP dimers
may form via alternative mechanisms involving regions of the extracellular
domain (30–32) or consecutive GxxxG motifs more downstream of the Ab
N-terminus (28). With increasing cluster size, APP molecules become
immobile and locally provide more binding sites for the endocytic
machinery, favoring full clathrin assembly or sorting to clathrin structures,
internalization, and amyloidogenic processing. Interference with the clus-
tering reaction from the extracellular site would increase the time APP
resides in the plasma membrane and thereby the chance to be cleaved by
a-secretase, resulting in nonamyloidogenic processing.
1416 Schreiber et al.trafficking, which is intriguing for two reasons: first, the
Ab domain initiates its own intracellular production, and
second, the finding is medically relevant, as it suggests a
new route for battling Alzheimer’s disease.SUPPORTING MATERIAL
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